Business Wire

New Research Concludes EU will Miss Climate Goals Unless Cleantech Innovation Is Scaled

23.3.2021 12:37:00 EET | Business Wire | Press release

Share

Newly-published research from Cleantech Group®, the global authority on clean technology innovation, with the support of Breakthrough Energy, found the EU’s venture capital investment into cleantech from 2011-2020 grew by a remarkable 7.5x to more than EUR 5 billion in 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005539/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

EU Cleantech Venture Capital Investment grew by 7.5x between 2011 and 2020 (Cleantech Group)

But research also discovered progress is concentrated on early-stage development and lacks scale-up investment and policy support. The EU attracted 23% of global cleantech seed-stage funding in 2020, but only 7% of global cleantech growth equity funding (compared to 54% for North America). The EU risks missing key climate targets by failing to scale clean technologies and letting promising innovators scale in North America and Asia instead.

Cleantech for Europe is a new initiative launched by Cleantech Group®, with the support of Breakthrough Energy, to help the EU lead the global clean transformation through targeted research and recommendations on EU cleantech investment and policy. The initiative connects EU policy makers to entrepreneurs and investors.

Its first position paper, published today, Making Fit for 55 a green demand shock to scale EU cleantech, analyses the EU cleantech landscape. It advocates for leveraging the EU’s upcoming Fit for 55 regulatory package to create leadership in five key innovation sectors: green hydrogen, green steel, low-carbon construction materials, sustainable aviation and soil carbon. The paper makes the case for a green demand shock that would pull EU innovators to continental scale and maximize climate impact.

“The EU’s climate future is at a crossroads. Deploying mature technologies such as solar and wind can only take us halfway. To lead the race to net zero, and gain a competitive advantage for decades, the EU needs a green demand shock to scale early-stage clean technologies” said Jules Besnainou, Director, Cleantech Group.

“With the forthcoming ‘Fit for 55’ package, the EU will update almost all of its energy and climate legislation, changing the policy framework for a long time to come. With investment cycles averaging 25 years, what happens in 2050 is essentially being decided today. The stakes couldn’t be higher as only a new generation of clean technologies can lead Europe towards climate neutrality. That is why this study sheds light on persistent challenges in the European innovation ecosystem that urgently need to be addressed – from lack of growth equity and weak demand signals for green products to poor exit routes for successful entrepreneurs” said Ann Mettler, Vice President, Europe, Breakthrough Energy.

Link to research: https://www.cleantechforeurope.com/

About Cleantech Group
At Cleantech Group, we provide research, consulting and events to catalyze opportunities for sustainable growth powered by innovation. We bring clients access to the trends, companies and people shaping the future and the customized advice and support businesses need to engage external innovation. Industries are undergoing definitive transitions toward a more digitized, de-carbonized and resource-efficient industrial future. At every stage from initial strategy to final deals, our services bring corporate change makers, investors, governments and stakeholders from across the ecosystem, the support they need to thrive in this fast-arriving and uncertain future.

The company was established in 2002 and is headquartered in San Francisco with people based in London, Paris and Boston.

About Breakthrough Energy
Founded by Bill Gates, Breakthrough Energy is dedicated to helping humanity avoid a climate disaster. Through investment vehicles, philanthropic programs, policy advocacy, and other activities, we’re committed to scaling the technologies we need to reach net-zero emissions by 2050. For more information about Breakthrough Energy visit breakthroughenergy.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jules Besnainou
Director, Cleantech Group
hello@cleantechforeurope.com
+33 6 23 12 00 08

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye